Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low.
van Dijk D, Vermij L, León-Castillo A, Powell M, Jobsen J, Leary A, Bowes D, Mileshkin L, Genestie C, Jürgenliemk-Schulz I, de Kroon C, Post C, de Boer S, Nooij L, Kroep J, Creutzberg C, Smit V, Horeweg N, Bosse T, Westermann A. van Dijk D, et al. Among authors: creutzberg c. J Clin Oncol. 2024 Oct 7:JCO2302768. doi: 10.1200/JCO.23.02768. Online ahead of print. J Clin Oncol. 2024. PMID: 39374474
Survival after relapse in patients with endometrial cancer: results from a randomized trial.
Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van der Steen-Banasik E, Beerman H, van Lent M; PORTEC Study Group. Creutzberg CL, et al. Gynecol Oncol. 2003 May;89(2):201-9. doi: 10.1016/s0090-8258(03)00126-4. Gynecol Oncol. 2003. PMID: 12713981 Clinical Trial.
Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review.
Scholten AN, van Putten WL, Beerman H, Smit VT, Koper PC, Lybeert ML, Jobsen JJ, Wárlám-Rodenhuis CC, De Winter KA, Lutgens LC, van Lent M, Creutzberg CL; PORTEC Study Group. Scholten AN, et al. Among authors: creutzberg cl. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):834-8. doi: 10.1016/j.ijrobp.2005.03.007. Epub 2005 May 31. Int J Radiat Oncol Biol Phys. 2005. PMID: 15927414 Clinical Trial.
Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial.
Nout RA, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Stenfert Kroese MC, van Bunningen BN, Smit VT, Nijman HW, van den Tol PP, Creutzberg CL. Nout RA, et al. Among authors: creutzberg cl. J Clin Oncol. 2009 Jul 20;27(21):3547-56. doi: 10.1200/JCO.2008.20.2424. Epub 2009 Jun 22. J Clin Oncol. 2009. PMID: 19546404 Clinical Trial.
Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA, Smit VT, Putter H, Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik EM, Mens JW, Slot A, Kroese MC, van Bunningen BN, Ansink AC, van Putten WL, Creutzberg CL; PORTEC Study Group. Nout RA, et al. Among authors: creutzberg cl. Lancet. 2010 Mar 6;375(9717):816-23. doi: 10.1016/S0140-6736(09)62163-2. Lancet. 2010. PMID: 20206777 Clinical Trial.
Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial.
Nout RA, van de Poll-Franse LV, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, Lutgens LC, Pras B, van Putten WL, Creutzberg CL. Nout RA, et al. Among authors: creutzberg cl. J Clin Oncol. 2011 May 1;29(13):1692-700. doi: 10.1200/JCO.2010.32.4590. Epub 2011 Mar 28. J Clin Oncol. 2011. PMID: 21444867 Clinical Trial.
212 results